Skip to main content

Advertisement

Table 2 Estimation of annual economic impact

From: Economic contributions of pharmaceutical interventions by pharmacists: a retrospective report in Japan

Intervention type Number Cost savings assigned per case (USD) Total (USD) Intervention class
1 Avoidance of serious ADRs 12 21,400 256,800 Quality/safety improved
2 Transvenous antimicrobial therapy interventions 172 1900 325,080 Pharmacotherapy improved
3 Switch from intravenous to oral administration Voriconazole 55 165.1 9078 Cost saving
Linezolid 32 96.9 3099
4 Interventions concerning cancer chemotherapy 82 1120 91,840 Pharmacotherapy improved
5 Avoidance of drug interactions High risk 2 840 1680 Pharmacotherapy improved
Normal 56 560 31,360
6 Renal dosing recommendations High risk 7 840 5880 Pharmacotherapy improved
Normal 43 560 24,080
7 Intravenous drug compatibility High risk 1 840 840 Pharmacotherapy improved
Normal 2 560 1120
8 Confirmation of medication history (presurgical cessation of antiplatelet drugs) High risk 13 840 10,920 Quality/safety improved
Normal 4 560 2240
9 Drug therapy consultation or recommendations High risk 34 840 285,60 Pharmacotherapy improved
Normal 149 560 834,40
10 Monitoring recommendations   19 0 0 Pharmacotherapy improved
11 Ward rounds, multidisciplinary teamwork ICT 28 0 0 Quality/safety improved
NST 45 0 0
PCT 52 0 0
12 Drug information   640 0 0 Provider education
13 ADRs reported to PMDA 4 0 0 Quality/safety improved
  Total 1452 - 876,017  
  1. ADRs serious adverse drug reactions, ICT infection control team, NST nutrition support team, PCT pain control team, PMDA Pharmaceutical and Medical Devices Agency